

# PEDIATRIC PHARMACOTHERAPY

A Monthly Newsletter for Health Care Professionals

Children's Medical Center at the University of Virginia

Volume 7 Number 1

January 2001

## Six-year Cumulative Index

(key term followed by volume/issue and type of citation:

M= main feature; L= literature review; F= FDA update)

<b>A</b>		Anticonvulsants, kinetics	1/12 L
ACE inhibitors	2/2 L		2/1 L
Acellular pertussis vaccine	3/2 L	Anticonvulsants, review	2/11 L
	3/7 M		6/10 L
	3/9 L	Anticonvulsants, withdrawal	4/4 L
Acetaminophen	2/7 M	Antiemetic guidelines	5/6 L
Acetaminophen, overdose	6/3 M		6/11 L
Acetaminophen, rectal	5/12 L	Antifungals, review	3/4 L
Acetaminophen, renal effects	1/6 L	Antihistamines	1/9 M
Acetaminophen, TEN with	6/3 L	Antineoplastics, endocrine effect	3/2 L
Aclometasone	2/1 M	Antipyretics	2/7 M
Adverse reactions, frequency	2/10 L	Antipyretics, kinetics/dynamics	5/8 L
	4/11 L	Ardeparin	3/6 M
Adverse reactions, reporting	1/3 M	Arrhythmias, drug-induced	3/11 L
Adverse reactions, causality	2/11 L	Astemizole	1/9 M
Albuterol	2/5 M	Asthma, magnesium in	5/7 L
Alprostadil (PGE <sub>1</sub> )	6/9 M	Asthma, single isomer therapy	6/1 L
Alteplase	5/8 M	Asthma, steroids	1/1 L
Alteplase, use in ECMO	5/6 L	Asthma, therapy in teens	1/8 L
Alternative therapies	4/5 M	Atenolol, use in Marfan syndr.	1/5 L
Amcinonide	2/1 M	Atropine	2/12 M
Amiloride, kinetics	3/5 L	Attention Deficit, therapy	1/12 M
Aminoglycosides, in transplant	3/11 L		4/10 L
Amoxicillin, adverse effects	5/3 L	Autism, therapy	1/2 L
Ampicillin, oral in neonates	4/1 L	Azithromycin	2/2 M
Analgesics, dosing	4/2 L		4/9 L
Anesthetics, adverse effects	4/11 L	Azithromycin, kinetics	3/11 L
Antiarrhythmics, pregnancy	5/5 L		
Antibiotics, allergies	1/12 L	<b>B</b>	
Antibiotics, comparison of oral	2/4 L	Bayesian kinetics	3/2 L
Antibiotics, nephropathy from	5/7 L	Benzalkonium chloride	2/9 M
Antibiotics, selection	4/7 L	Benzyl alcohol	2/9 M
Antibiotics, use in infants	5/11 L		

Betamethasone	2/1 M
Betamethasone, adverse effects	3/11 L
Bone marrow trans., gentamicin	3/11 L
Bone marrow trans., tobramycin	3/11 L
Breastfeeding, drugs during	1/12 L
Breastfeeding, effect on liver	2/2 M
Brompheniramine	1/9 M
Budesonide	4/10 L
Bumetanide	1/10 M
Buprenorphine, withdrawal	4/2 L
<b>C</b>	
Caffeine	1/3 L 5/12 M
Caffeine, kinetics	3/8 L
Calcium chloride	2/12 M
Carbamazepine	2/11 M
Carbamazepine/Cyclosporine	1/6 L
Carbamazepine, drug interact.	2/10 L
Carbamazepine/Grapefruit juice	4/11 L
Carbamazepine, hepatorenal fail.	5/7 L
Cardiovascular drugs, kinetics	1/1 L
Catheters, saline vs. heparin	4/4 L
Cefaclor	2/6 M
Cefadroxil	2/6 M
Cefepime	1/8 L 3/2 L 5/5 M
Cefixime	2/6 M
Cefpodoxime	2/6 M
Cefprozil	2/6 M
Ceftazidime	1/4 L
Ceftazidime, use in infants	2/2 L
Ceftibuten	2/6 M 3/11 L
Ceftriaxone	3/2 M
Cefuroxime axetil	2/6 M 2/7 L
Cefuroxime, during pregnancy	6/4 L

Cephalexin	2/6 M
Cephalosporins, review of oral	2/6 M
Cephradine	2/6 M
Cetirizine, use in infants	3/4 L
Chlorothiazide	1/10 M
Chlorpheniramine	1/9 M
Ciprofloxacin	4/12 M
Cisapride, drug interactions	2/11 M
Clarithromycin	2/2 M
Clarithromycin/Itraconazole	5/12 L
Clarithromycin, kinetics	6/1 L
Clemastine	1/9 M
Clobetasol	2/1 M
Clocortolone	2/1 M
Clonazepam, kinetics	2/3 L
Clonidine	1/12 M
Clonidine, use in ADHD	6/2 L
Clostridium difficile	6/6 M
Combination vaccines	3/7 M
Compliance	1/4 L 3/8 M 5/11 L
Compliance, effect of taste	3/11 L
Conscious sedation	2/3 L
Corticosteroids, topical	2/1 M
Co-trimoxazole	4/4 M
Creatinine clearance, predicting	1/10 L
Cromolyn	5/7 M
Crotamiton	1/8 M
Croup, management	3/5 L
Cyclic antidepressant toxicity	1/5 L
Cyclosporine	1/4 M
Cyclosporine, absorption of	2/3 L
Cyclosporine/Carbamazepine	1/6 L
Cyclosporine, drug interactions	2/4 L
Cyclosporine, dynamics	5/10 L
Cyclosporine, kinetics	3/7 L
Cyclosporine/Norfloxacin	1/11 L
Cystic fibrosis, drug metabolism	1/1 L
Cystic fibrosis, ibuprofen in	5/5 L
Cystic fibrosis, kinetics	5/2 L

Cystic fibrosis, therapy	1/11 L
Cystic fibrosis, tobramycin in	2/5 L
Cytochrome P450 enzymes	1/7 L 3/5 M 4/3 L 6/2 L
<b>D</b>	
d-penicillamine, dosing	6/7 L
Dalteparin	3/6 M
Depression, treatment of	5/2 L
Desensitization, antimicrobials	3/11 L
Desonide	2/1 M
Desoximetasone	2/1 M
Dexamethasone	2/1 M
Dextroamphetamine	1/12 M
Diflorasone	2/1 M
Digoxin, drug interactions	1/4 L
Dilution of medications	1/8 L
Diphenhydramine	1/9 M
Diuretics	1/10 M
Dornase alpha	1/1 L 2/3 L
Dornase alpha, cost analysis	1/6 L
Doxepin, breastfeeding with	5/9 L
Doxepin, toxicity/topical use	6/7 L
Drug administration in vent.	5/5 L
Drug approval process, FDA	1/11 M
Drug, expenditures	4/3 L
Drug interactions, renal	4/7 L
Drug labeling, pediatrics	3/9 F
Drug-nutrient interactions	1/5 M
Drug reactions, idiosyncratic	2/10 L
Dyes and colorants	2/9 M
<b>E</b>	
Eicosanoid research	4/9 L
EMLA, use with SC injections	2/1 M
EMLA, use for LPs	3/11 L
Enoxaparin	3/6 M
Enteral feedings/Phenytoin	6/9 L
Epilepsy, treatment	2/4 L
Epinephrine	2/12 M
Epoetin	1/3 L

	5/12 M 6/7 L
Epoetin, enteral administration	6/11 L
Erythema multiforme	4/11 M
Erythromycin	2/2 M
Erythromycin/Sertraline	5/9 L
Erythropoietin kinetics	5/2 L
Ethanol	2/9 M
Etoposide, kinetics/dynamics	1/9 L
Excipients, pharmaceutical	2/9 M
Extravasations, IV	4/1 M
<b>F</b>	
Famotidine	2/9 L 4/2 M
Famotidine, kinetics/dynamics	2/3 L
Felbamate, review	5/11 L
Flavorings	2/9 M
Fluconazole	3/12 M
Fluconazole, kinetics	1/2 L
Fluconazole/Warfarin	2/5 L
Fluocinolone	2/1 M
Fluocinonide	2/1 M
Fluoxetine	2/10 M
Flurandrenolide	2/1 M
Fluticasone	2/1 M
Fluvoxamine	2/10 M
Food and Drug Administration	1/11 M 6/12 M
Furosemide	1/10 M
Furosemide, bolus vs. intermitt.	4/3 L
<b>G</b>	
Gabapentin, aggression with	4/6 L
Gabapentin, stability in food	4/5 L
G-CSF	1/1L
G-CSF, binding to catheters	1/2 L
G-CSF, enteral administration	6/11 L
Gentamicin, neonatal dosing	1/7 L
Gentamicin monitoring	4/1 L
Gentamicin, use in leukemics	2/1 L
Gestational diabetes, therapy	2/7 L

Glovers, permeab. to chemo.	5/12 L
Granisetron	3/9 M
Grapefruit juice/Carbamazepine	4/11 L
Group B Strep. ,therapy	3/8 L
Growth hormone	3/7 L
<b>H</b>	
Halbetasol	2/1 M
Halcinonide	2/1 M
Half-life	1/7 M
Halving methylphenidate	3/11 L
Halving tablets	4/3 L
Heparin, dynamics	3/5 L
Heparin vs. saline in catheters	4/4 L
Herbal medicines	3/11 L 4/5 M 6/4 L
HIV, therapy in children	1/6 L
HMG-CoA reductase inhibitors	5/12 L
Hydrochlorothiazide	1/10 M
Hydrocortisone	2/1 M
Hydroxyurea, use in pregnancy	6/1 L
Hypercholesterolemia	3/6 L
Hypertension, treatment	1/1 L 6/5 L
<b>I</b>	
Ibuprofen	2/7 M
Ibuprofen, overdose	1/10 L 4/9 L
Ibuprofen, pyloric stricture	5/9 L
Ibuprofen, renal toxicity	6/4 M
Ibuprofen, use in CF	5/5 L
Idiosyncratic drug reactions	2/10 L
Ifosfamide, metabolites	4/6 L
Imipenem-cilastatin	2/2 L
Immune globulin, use in HIV	1/5 L
Indinavir, nephrotoxicity	3/11 L
Infliximab	5/11 M
INR	1/1 M
Internet, as information source	5/6 M 5/12 L
Isoniazid	1/2 L

Isoniazid, kinetics	3/11 L
Isradipine	3/7 L
Itraconazole/Clarithromycin	5/12 L
IV extravasations	4/1 M
<b>J</b>	
JRA, therapy	5/12 L
<b>K</b>	
Kawasaki syndrome, therapy	5/12 L
Kernicterus, prevention	4/7 L
Ketogenic diet	4/4 L
Ketorolac	3/6 L
Ketorolac, kinetics	5/7 L
<b>L</b>	
Lamotrigine	1/3 L 1/12 L 5/3 M
Lamotrigine, dose relationships	3/8 L
Lamotrigine, kinetics	5/7 L
Lansoprazole	5/4 M
Levalbuterol, assessment	5/3 L
Lice, treatment	1/8 M
Lindane	1/8 M
Loracarbef	2/6 M
Loratadine	1/9 M
Low-molecular-weight heparins	3/6 M
<b>M</b>	
Macrolides	2/2 M 3/4 L 5/2 L
Macrolides, drug interactions	1/9 L
Magnesium, use in asthma	5/7 L
Malathion	1/8 M
Measles vaccine, review	5/2 L
Medication errors, prevention	1/1 L 5/10 M
Medication taste, compliance	3/11 L
MedWatch	1/3 M
MedWatch, data from	1/8 L
Menstrual cycle, metabolism	4/6 L
Meropenem	3/10 L 4/7 M

Metered-dose inhalers, changes	4/3 L
Methemoglobinemia	2/8 L
Methotrexate, kinetics	1/4 L
Methylphenidate	1/12 M 3/10 L
Methylphenidate, halving tabs	3/11 L
Methylphenidate, kinetics	5/10 L 6/2 L
Methylphenidate, tolerance	6/1 L
Metoclopramide	1/3 L
Metoclopramide, kinetics	4/5 L
Metolazone	1/10 M
Midazolam	4/9 L 6/1 M
Midazolam, clearance	2/2 L
Midazolam, compatibility	1/12 L
Midazolam, intranasal	2/5 L
Midazolam, use in neonates	1/2 L
Milk:Plasma ratio	2/4 M
Mineral supplements	3/2 M
Minocycline-induced lupus	3/11 L
Mirtazapine	6/2 M
Modernization Act, FDA	6/12 M
Mometasone	2/1 M 5/12 M
Montelukast	4/10 M
Moricizine	1/12 L
Morphine, use in neonates	1/1 L
Muromonab-CD3, anaphylaxis	6/2 L
Mycophenolate	4/1 L 4/8 M
<b>N</b>	
Nalmefene, dosing/kinetics	6/9 L
Naloxone	2/12 M
Nebulizer solutions, preservative	4/3 L
Nedocromil	5/7 M
New drug development	1/7 L
Non-prescription medications	1/5 L
Norfloracin/Cyclosporine	1/11 L
NSAIDs, renal effects	1/6 L

<b>O</b>	
Obesity, therapy	3/11 L
Omeprazole	5/4 M
Ondansetron	3/9 M
Ondansetron, kinetics	1/11 L
Ondansetron, outpatient use	1/2 L
Opiates, respiratory depression	2/3 L
Opioids, tolerance and depend.	6/7 M
Oral contraceptives	1/3 L
Oseltamivir	6/12 F
Otitis media, therapy	4/10 L
Over-the-counter recommend.	4/9 L
<b>P</b>	
Pain management	2/3 L 2/6 L
Palivizumab	4/9 M 6/2 L
Parenteral nutrition	1/3 L 5/12 L
Paroxetine	2/10 M
Patient-controlled analgesia	6/11 M
Patient education	3/8 M
Pediatric pharmacology library	1/6 M
Pemoline	1/12 M
Pemoline, liver failure	1/8 L 4/5 L
Permethrin	1/8 M
PGE <sub>1</sub>	6/9 M
Pharmacists' OTC recommend.	4/9 L
Phenobarbital, dialysis	3/10 L
Phenobarbital, ECMO	5/6 L
Phenothiazines, review	5/10 L
Phenytoin	2/8 M
Phenytoin, con. in neonates	4/4 L
Phenytoin/Enteral feedings	6/9 L
Phosphate overdose	3/12 L
Photosensitivity, drug-induced	4/6 M
Placebo response	2/11 L
Placental drug transfer, model	2/1 L

Placental drug transfer, mech.	1/4 L
Pneumococcal vaccine	5/12 M 6/8 M
Polio vaccine	3/7 M
Poison prevention	1/3 M 2/3 M 4/3 M
Polyethylene glycol	2/9 M
Portactant	5/12 M
Pregnancy, antiarrhythmics use	5/5 L
Pregnancy, cefuroxime use	6/4 L
Pregnancy, hydroxyurea use	6/1 L
Pregnancy, labeling changes	6/12 F
Pregnancy, metabolic function	3/11 L
Preservatives	2/9 M
Preservatives, nebulizer solution	4/3 L
Propylene glycol	2/9 M
Propafenone, during CVVH	5/10 L
Propofol	6/5 M
Prostaglandin E <sub>1</sub>	6/9 M
Proton pump inhibitors	5/4 M
Psychiatric disorders, therapy	2/6 L
Psychotropic use, predicting	1/12 L
Pyrethrins	1/8 M
<b>Q</b>	
Quinine	5/6 L
<b>R</b>	
Recent advances in pharmacol.	1/2 L
Renal drug interactions	4/7 L
Respiratory syncytial virus	3/10 M 4/2 L 4/9 M
Ribavirin	3/10 M
Risperidone, toxicity	2/5 L
Rocuronium	6/10 M
Rotavirus vaccine	5/2 M 6/12 F
RSVIG (prophylaxis)	3/10 M 4/9 M 6/2 L

<b>S</b>	
Saline vs. heparin in catheters	4/4 L
Salmeterol	1/1 F
Scabies, treatment	1/8 M 2/8 L
Scientific bias	3/9 L
Sedatives	4/10 L
Sedatives, kinetics in neonates	3/3 L
Selective 5HT <sub>3</sub> Reuptake Inhib.	2/10 M
Sertraline	2/10 M
Sertraline/Erythromycin	5/9 L
Serum sickness, cross-sensitivity	4/7 L
Sinusitis, therapy review	6/7 L
Skin reactions, drug-induced	1/9 L 4/11 M
Smoking cessation	1/3 L
Sodium bicarbonate	2/12 M
Solvents	2/9 M
Spirolactone	1/10 M
Splitting tablets	4/3 L
Stevens-Johnson syndrome	4/11 M
Sufentanil, intranasal	2/5 L
Sulfamethoxazole-trimethoprim	4/4 M
Supraventricular tachycardia	4/6 L
Surfactants	2/3 L 4/9 L
SVT, treatment	4/6 L
Sweeteners	2/9 M
<b>T</b>	
Tacrolimus	4/2 L
Tacrolimus, effect of feeds	4/8 L
Tacrolimus, rescue therapy	4/10 L
Taste, effect on compliance	3/11 L
Terfenadine	1/9 M
Terfenadine, breastmilk transfer	1/5 L
Theophylline, dosing	1/4 L 1/9 L
Theophylline, drug interactions	1/5 L

Therapeutic drug monitoring	1/7 M
Therapeutic equivalence	2/12 L
Ticarcillin/clavulanic acid	1/9 L
Tobramycin, CF dosing	2/5 L
Tobramycin, lung transplant	4/6 L
Tobramycin, neonatal kinetics	3/11 L
Topiramate	4/5 L 5/12 M
Toxic epidermal necrolysis	4/11 M
Triamcinolone	2/1 M
Trimethoprim-sulfamethoxazole	4/4 M
<b>U</b>	
Urosdeoxycholic acid in CF	3/11 L
<b>V</b>	
Vaccines	3/7 M
Vaccines, adverse reactions	1/3 M 3/7 M
Vaccines, storage	1/6 M
Valproic acid	3/3 M 5/7 L
Valproate, kinetics	1/12 L
Vancomycin	1/2 M 3/9 L 5/12 L
Vancomycin, monitoring	3/8 L
Vancomycin, neonatal kinetics	3/11 L
Vancomycin-resistant organisms	1/2 M
Varicella vaccine	1/2 F
Vecuronium	5/9 M
Vitamin supplements	3/4 M
Vitamin K	1/4 L
Volume of distribution	1/7 M
<b>W</b>	
Warfarin	1/1 M
Warfarin/Fluconazole	2/5 L
Warfarin, kinetics	6/12 L
<b>X-Z</b>	
Zafirlukast	5/12 M
Zidovudine, drug	4/1 L

<b>interactions</b>	
Zidovudine, kinetics in infants	5/9 L
Zidovudine, use in pregnancy	1/8 L
Zinc, use in common cold	4/2 L